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Abstract
Background: The introduction of targeted treatments for subsets of non-small cell lung cancer (NSCLC) has
highlighted the importance of accurate molecular diagnosis to determine if an actionable genetic alteration
is present. Few data are available for Central and Eastern Europe (CEE) on mutation rates, testing rates, and
compliance with testing guidelines.
Methods: A questionnaire about molecular testing and NSCLC management was distributed to relevant specialists in
nine CEE countries, and pathologists were asked to provide the results of EGFR and ALK testing over a 1-year period.
Results: A very high proportion of lung cancer cases are confirmed histologically/cytologically (75–100%), and
molecular testing of NSCLC samples has been established in all evaluated CEE countries in 2014. Most countries follow
national or international guidelines on which patients to test for EGFR mutations and ALK rearrangements. In most
centers at that time, testing was undertaken on request of the clinician rather than on the preferred reflex
basis. Immunohistochemistry, followed by fluorescent in situ hybridization confirmation of positive cases, has
been widely adopted for ALK testing in the region. Limited reimbursement is a significant barrier to molecular
testing in the region and a disincentive to reflex testing. Multidisciplinary tumor boards are established in most of the
countries and centers, with 75–100% of cases being discussed at a multidisciplinary tumor board at specialized centers.
Conclusions: Molecular testing is established throughout the CEE region, but improved and unbiased reimbursement
remains a major challenge for the future. Increasing the number of patients reviewed by multidisciplinary boards
outside of major centers and access to targeted therapy based on the result of molecular testing are other major
challenges.
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Background
Globally, for several decades, lung cancer has been the
most common cancer and the leading cause of cancer
deaths. The situation is particularly serious in Central
and Eastern European (CEE) countries, which have the
highest age-standardized incidence rates in men around
the world [1]. Incidence rates in women are generally
lower than in men, but are increasing in many countries
worldwide. There are some geographical differences in
incidence, reflecting in part the different historical
exposure to tobacco smoking [1]. The diagnosis is often
not made until late in the course of the disease and, as a
result, only a minority of patients are cured and the ratio
of mortality-to-incidence is very high. Almost 70% of
patients have locally advanced or metastatic disease at
initial diagnosis [2].
Nowadays, only about 15% of lung cancer cases are
small cell lung cancer, with the majority of lung cancer
cases classified as non-small cell lung cancer (NSCLC).
When the diagnosis is made based on a small biopsy or
cytology sample, besides the three common types of
NSCLC (squamous cell carcinoma, adenocarcinoma, and
non-small cell carcinoma not otherwise specified [NOS])
several additional subtypes can be defined by morphology,
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immunohistochemistry (IHC), and molecular pathology
[2, 3]. Although most lung cancers are attributable to
tobacco smoking, approximately 10–15% of cases in
Western countries occur in lifelong never-smokers and
these are almost exclusively adenocarcinomas [4].
The study of molecular biology of NSCLC has had a
major impact on diagnosis and treatment of this disease
[5–7]. The work of the Lung Cancer Mutation Consortium
and other groups has shown that driver mutations or other
oncogene alterations are present in more than half of all
adenocarcinomas [8]. The discovery of targetable genetic
alterations, such as activating mutations of the epidermal
growth factor receptor (EGFR) and anaplastic lymphoma
kinase (ALK) rearrangements, has led to the implementa-
tion of precision therapy for certain subtypes of lung cancer
based on appropriate patient selection [9]. Clinical trials
have shown significantly longer progression-free survival in
patients with EGFR mutations who are treated with EGFR
tyrosine kinase inhibitors (TKIs) compared with chemo-
therapy [10]. Similarly, ALK TKI treatment of patients with
ALK-rearranged tumors prolongs progression-free survival
compared with first-line chemotherapy [11]. Patients with a
druggable molecular alteration who are treated with a cor-
responding targeted treatment benefit from significantly
higher response rates and longer progression-free survival,
although an improvement in overall survival with targeted
agents has not been shown by the majority of randomized
clinical trials [8]. There are probably multiple reasons for
the lack of overall survival advantage seen in clinical trials,
one of the most important reasons is a high number of
patients crossing over to targeted agents after failure of
treatment in the chemotherapy arms.
This move towards biomarker-based treatment ap-
proaches has highlighted the importance of accurate
molecular diagnosis. In addition to classical morphologic
classification, molecular analysis of tumor samples is es-
sential to determine if a druggable oncogenic alteration
is present. Consequently, the pathologist is now a key
member of the multidisciplinary lung cancer team [12].
Identification of the challenges for personalized lung
cancer treatment within the CEE region might facilitate
molecular diagnostics and improve patient care. Infor-
mation about molecular testing practices for NSCLC in
the CEE region is relatively limited. The INSIGHT study
has provided some information on EGFR mutation rates,
testing, and compliance with testing guidelines in several
Central European countries [13]. However, only very few
data from this region are available on ALK testing. Our
study was designed to collect information on both EGFR
and ALK testing from a large number of CEE countries.
Methods
A Working Group of oncologists, pulmonologists, and
pathologists from the CEE region was established to
obtain more information on NSCLC molecular testing
in their countries and to raise awareness of the current
issues around personalized medicine for lung cancer.
As a first step, a questionnaire (Additional file 1) with
37 questions addressing issues of molecular testing and
NSCLC management was distributed in the second
quarter of 2014 to 59 specialists (epidemiologists, oncol-
ogists, pulmonologists, and pathologists) from nine CEE
countries. In June 2015, pathologists were also asked to
provide details of the results of EGFR and ALK testing
over a 1-year period.
Results
Respondents
There were a total of the 42 responses from nine coun-
tries; the number of responders by country are shown in
Table 1 (data were not available for some questions; see
Additional file 1 for the questionnaire).
Lung cancer types
Table 2 shows the proportion of lung cancer cases that
are confirmed morphologically in each country.
Figure 1 shows the breakdown of lung cancer types for
selected countries. Adenocarcinoma is the most com-
mon type in all countries except Bulgaria, whereas small
cell lung cancer represented between 10% and 20% of
cases in all countries.
EGFR testing
Most countries have national guidelines or follow
European guidelines on EGFR mutation testing [2].
European guidelines are followed in Bulgaria, Croatia,
Israel, Slovakia, Slovenia, and Turkey. Bulgaria, Czech
Republic, Hungary, Israel, Poland, and Slovakia also have
national guidelines, whereas some centers in Poland fol-
low local guidelines. Some Turkish centers follow
American College of Pathologists guidelines [12].
Most centers reported that adenocarcinomas and
NSCLC-NOS were tested for activating EGFR mutations.
In some countries (Bulgaria, Czech Republic, Israel,
Slovakia, Slovenia, and Turkey), large cell and squamous
Table 1 Countries participating and number of responders
Bulgaria 2
Croatia 4
Czech Republic 4
Hungary 8
Israel 3
Poland 7
Slovakia 7
Slovenia 3
Turkey 4
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cell tumors may be tested in selected cases (mostly on
request from the treating physician). In most countries,
only advanced tumors (stage IIIb and IV) were generally
tested for EGFR mutations. In the Czech Republic,
Slovakia, and Slovenia, as well as in certain individual
centers in other countries, other stages were also tested
for research purposes.
In most centers, EGFR mutation testing was under-
taken when requested by the clinician, usually the on-
cologist treating the patient. In the Czech Republic,
Slovakia, and Slovenia, and some centers in Croatia,
testing was reflex (i.e. the pathologist automatically
tested all tumors that met the criteria). In Hungary, it is
policy to test for KRAS mutations first, and the presence
of a KRAS mutation is an exclusion criterion for EGFR/
ALK testing. In Turkey, EGFR/ALK testing is not per-
formed in KRAS mutation-positive tumors, although
KRAS testing is not routine.
In many countries (Croatia, Czech Republic, Hungary,
Israel, Slovakia, and Slovenia), at least 65% of eligible tu-
mors were actually tested for EGFR mutations in 2014.
However, a significant proportion of samples (5–25%)
were inadequate for testing, usually because the sample
was too small or did not contain enough tumor cells.
Usually, more than one method was used in each
country for EGFR mutation testing. Real-time polymer-
ase chain reaction (PCR) was used in all countries, direct
sequencing in five countries, and other methods were
used in addition in only two countries.
The incidence of specific EGFR mutations in selected
centers in 2014 is shown in Table 3; the frequency of
EGFR-mutated tumors ranged from 6.7 to 15.2%. These
numbers cannot be compared because of the different
inclusion criteria for testing.
ALK testing
ALK testing is available in all countries except Bulgaria.
Most countries have national guidelines or follow Euro-
pean guidelines on which subtypes to test for ALK rear-
rangements. European guidelines [2] are followed in
Croatia, Slovenia, and Turkey, whereas Czech Republic,
Hungary, Israel, Poland, and Slovakia follow national
guidelines. In all centers, adenocarcinomas and NSCLC-
NOS were tested, usually on request from the treating
clinician. As for EGFR testing, reflex ALK testing for all
eligible patients was implemented in the Czech Republic,
Slovakia, and Slovenia.
In most countries, as for EGFR testing, only advanced
tumors (stage IIIb and IV) were tested for ALK
rearrangements. At some centers in Croatia, Czech
Republic, Slovakia, and Slovenia, other stages were also
tested for research purposes. The presence of a known
EGFR mutation was an exclusion criterion for ALK test-
ing in all countries. In addition, in countries where some
or all samples are tested for KRAS mutations (Turkey,
Table 2 Lung cancer cases morphologically confirmed
Country (number of responses) Proportion of cases, %
Bulgaria 75*
Croatia 100*
Czech Republic 85†
Israel 100*
Slovakia 83*
Slovenia 92*
*Registry data; †Best estimate
0
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60
Adeno Squamous NSCLC-NOS Small cell Large cell NE Large cell Other
Bulgaria Czech R Hungary Poland Slovakia Slovenia Turkey
Fig. 1 Lung cancer subtypes by country. NE, neuroendocrine carcinoma; NOS, not otherwise specified; NSCLC, non-small cell lung cancer
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Slovenia, Hungary, and Poland), the presence of a KRAS
mutation is also an exclusion criterion. For ALK testing,
IHC followed by fluorescent in situ hybridization (FISH)
and/or FISH alone were used in all countries. In Israel,
other methods, including next-generation DNA sequen-
cing, were also used (Table 4).
The incidence of ALK rearrangements determined in
selected centers in 2014 is shown in Table 5. The sub-
stantial differences in the frequency, which ranged from
1.6% to 12%, are most probably due to different testing
approaches, excluding KRAS- and EGFR-positive cases
from ALK testing or not.
Testing for other mutations
Tumor samples were tested routinely for KRAS muta-
tions in Hungary and Slovenia; some samples were
tested in Turkey and Poland. ROS1 testing was routine
in Slovenia and was undertaken on request in Slovakia.
Reimbursement for molecular testing
There are several different sources of funding for EGFR
and ALK testing in the region. In the Czech Republic,
Hungary, Israel, Poland, Slovakia, Slovenia, and Turkey,
testing is partly or fully reimbursed by the national
Table 3 Results of EGFR testing in selected centers in 2014a
EGFR, n (%) Non-diagnostic
WT Mut exon 18 Mut exon 19 Mut exon 20 Mut exon 21
Croatia (Zagreb) 561 (85.9) 8 (1.2) 46 (7) 8 (1.2) 30 (4.6) 11
Czech (Prague) 154 (90.6) 4 (2.4) 6 (3.5) 2 (1.2) 4 (2.2) 15
Czech (Hradec Kralove) 234 (90.0) 0 15 (5.8) 2 (0.8) 9 (3.5) 6
Hungary (Budapest, Timár) 350 (85.6) 4 (1.0) 22 (5.4) 14 (3.9) 19 (4.6) 57
Hungary (Budapest, Toth) 251 (93.3) 0 9 (3.3) 1 (0.4) 8 (3.1) 2
Hungary (Budapest, Kovalszky) 500 (88.5) 6 (1.1) 27 (4.8) 0 32 (5.7) –
Hungary (Debrecen) 760 (89.6) 0† 61 (7.2) 0† 27 (3.2) 13
Hungary (Pécs) 112 (86.8) 0 10 (7.8) 0 7 (5.4) –
Hungary (Szeged) 617 (92.6) 4 (0.6) 27 (4.1) 2 (0.3) 16 (2.4) 71
Slovakia 361 (87.6) 1 (0.2) 30 (7) 2 (0.5) 16 (3.8) –
Slovenia 464 (86) 5 (0.9) 39 (7.2) 8 (1.5) 25 (4.6) 57
Turkey (Cerrahpaşa) 714 (87.9) 17 (2.1) 52 (6.4) 3 (0.4) 26 (3.2) 38
EGFR epidermal growth factor receptor, WT wild-type
aNote that these numbers cannot be compared directly because of the different criteria for selection of samples to test
†Exons 18 and 20 not tested
Table 4 ALK testing methods
Croatia (Zagreb) IHC (IHC followed by FISH)
Czech (Hradec Kralove) IHC, IHC followed by FISH
Czech (Prague) IHC, IHC followed by FISH, FISH
Hungary (Budapest, Timár) FISH
Hungary (Budapest, Toth) FISH
Hungary (Budapest, Kovalszky) FISH, other
Hungary (Debrecen) FISH
Hungary (Pécs) IHC followed by FISH
Hungary (Szeged) FISH
Israel IHC, IHC followed by FISH, FISH,
sequencing
Poland (Warsaw) FISH
Slovakia IHC followed by FISH; FISH
Slovenia IHC followed by FISH
Turkey (Cerrahpaşa) IHC followed by FISH
FISH fluorescent in situ hybridization, IHC immunohistochemistry
Table 5 Results of ALK testing in selected centers in 2014a
ALK, n (%) Non-diagnostic
WT Rearrangement
Croatia 161 (93.1) 12 (6.9) 28
Czech (Prague) 55 (96.5) 2 (3.5) 10
Czech (Hradec Kralove) 260 (95.2) 13 (4.8) 2
Hungary (Budapest, Timár) 332 (94.9) 18 (5.1) 0
Hungary (Budapest, Toth) 122 (98.4) 2 (1.6) 4
Hungary (Budapest,
Kovalszky)
415 (95.6) 19 (4.4) 0
Hungary (Debrecen) 226 (91.5) 21 (8.5) 35
Hungary (Pécs) 55 (94.8) 3 (5.2) 2
Slovakia 375 (88) 51 (12) 0
Slovenia 199 (96.5) 7 (3.5) 0
Turkey (Cerrahpaşa) 764 (95.6) 35 (4.4) 14
ALK anaplastic lymphoma kinase, WT wild-type
aNote that these numbers cannot be compared directly because of the different
criteria for selection of samples to test; in some centers only samples negative for
KRAS and EGFR mutations were tested for ALK translocations
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health authority/national health insurance. Private insur-
ance covers some testing in Israel and Turkey.
The pharmaceutical industry supported some testing
in Hungary, Poland, and Slovenia, and was the only
source of financial support for testing in Bulgaria (EGFR
only) and Croatia (EGFR and ALK). The industry did
not finance testing in Czech Republic, Israel, Slovakia, or
Turkey. However, in the personal experience of the au-
thors, although the molecular testing is stated to be fully
reimbursed, this is not the case in practice. Often, there
are various forms of budget capping with a limitation on
the number of tests performed (e.g. based on the num-
ber of samples tested in the previous period). This policy
is a disincentive to reflex testing. In Hungary, for ex-
ample, only 30% of tests were reimbursed.
Multidisciplinary approach
Multidisciplinary lung cancer teams/tumor boards are
established in all countries; however, these are often only
functioning fully as part of routine clinical practice at
specialized lung cancer treatment centers. In Hungary,
Poland, and Slovenia, it is mandatory for all cases to be
discussed by a multidisciplinary tumor board. In Turkey,
it is obligatory for selected cases. When multidisciplinary
teams/tumor boards are operational, a pathologist is
usually a member.
The proportion of NSCLC cases actually discussed at a
multidisciplinary tumor board is 75–100% at most special-
ist centers; however, there is wide variation and can be as
low as 20% in some hospitals. There was a trend towards
a higher proportion of cases being discussed at multidis-
ciplinary tumor boards at respondents’ own centers com-
pared with their estimates for the country as a whole.
Data on how many patients with druggable EGFR or ALK
alterations get access to targeted drugs were not collected,
however according to the personal experience of the au-
thors, access to EGFR and/or ALK TKIs is often limited,
mainly due to local reimbursement policy restrictions.
Discussion
The survey confirmed that a very high proportion of
lung cancer cases are verified by histology or cytology
(75–100%) in CEE countries and that, in most countries,
the data can be derived from the established cancer
registries. Adenocarcinoma is the most common type in
all countries except Bulgaria, whereas 10–20% of cases
were small cell lung cancer in all countries, which is
consistent with global data [14]. The high incidence of
squamous cell carcinoma in Bulgaria may reflect the
high levels of smoking, relatively late introduction of fil-
tered cigarettes, and pollution levels [15].
It is encouraging that molecular testing of NSCLC
samples has been established in all CEE countries evalu-
ated in 2014, and that most countries follow national or
international guidelines on which patients to test for
EGFR mutations and ALK rearrangements. However, in
most centers, EGFR and ALK testing was undertaken on
request of the clinician, rather than automatically for eli-
gible samples (reflex testing), an approach which can
lead to delays in availability of test results and in the ini-
tiation of targeted treatment. There is an increasing
focus on shortening the turnaround time for test results,
and incorporation of reflex testing at the level of the
pathologist can help to avoid such delays [16].
The results showed that a significant proportion of
samples were unsuitable for testing for various reasons.
Various initiatives, including better communications as
well as educational initiatives directed at physicians who
collect tissue samples, may improve the situation and
help to ensure that samples are of sufficient size and
quality for molecular testing [16].
The results of molecular testing presented here
(Tables 3 and 5) provide interesting insights into the fre-
quency of EGFR mutations and ALK rearrangements in
the region. Yet only very limited general conclusions can
be drawn on the overall frequency of EGFR mutations
and ALK translocations because of the differences be-
tween centers in testing policy, selection of samples for
testing based on clinical factors (i.e. not all samples were
tested) and sequential testing at some centers resulting
in ALK testing being performed only on EGFR- and
KRAS-negative samples. Consistent with published data,
most EGFR mutations reported were in exons 19 and 21
[17, 18]. Information was not requested on KRAS muta-
tion rate, which would have been particular relevant for
Hungary where testing was routine. However, a recent
paper reported that the incidence of KRAS mutations
was 28.6% in 532 consecutive Caucasian patients tested
at Semmelweis University [19].
The results show that IHC, followed by FISH confirm-
ation in positive cases, had been widely adopted for ALK
testing in the region in 2014. FISH testing was still
regarded as the gold standard for ALK testing; however,
this method is relatively costly, time-consuming, and tech-
nically difficult to perform for routine use, which has led
to extensive evaluation of IHC as an alternative used for
screening purposes [20–22]. Data published after our sur-
vey showed that both D5F3 and 5A4 antibodies are able
to detect ALK rearrangements reliably and are equally well
suited for routine diagnostic use [23]. Several studies have
shown good concordance between the results of IHC and
FISH for ALK testing [24–27]. Indeed, some investigators
have shown that IHC can be useful in cases with atypical
or borderline FISH results [26, 28].
Acceptance by the United States Food and Drug Ad-
ministration (FDA) of the Ventana ALK D5F3 IHC as a
companion test to identify patients for crizotinib treat-
ment provides additional support for the routine use of
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IHC. The test provides a fast and accurate method to
identify ALK protein expression, with a binary scoring sys-
tem, and has been validated clinically by retrospective test-
ing of tissue samples from patients screened for inclusion
in crizotinib clinical trials [29]. These promising data en-
courage some centers to use IHC as a primary method re-
placing FISH. Immunohistochemistry can readily be
applied to tissue samples, cell blocks prepared from effu-
sions and Papanicolaou-stained cytologic slides [22, 27].
The European consensus recommended that all non-
squamous NSCLC tumors in patients with advanced/recur-
rent disease be tested for EGFR mutations and ALK
translocations. Selected squamous tumors (from patients
with minimal or remote smoking history) should be
strongly considered for testing. Sequential testing is not
recommended and parallel testing of multiple mutations
on the same sample is becoming the standard [2]. More re-
cent European recommendations are consistent with these
statements. Sanger sequencing, pyrosequencing, and next-
generation sequencing are recommended for EGFR testing
and validated tests including FISH and IHC may be used
for ALK testing [30]. Real-time PCR is also widely used.
National guidelines, where they exist, are broadly consistent
with these recommendations; in Hungary, KRAS testing is
performed before testing for other genetic alterations.
With the increasing number of molecular markers that
need to be examined for optimal selection of targeted
treatment, the cost of up-to-date molecular testing is
rapidly growing. The financial burden of testing the en-
tire cohort of eligible patients can, in fact, reach the cost
of the treatment of several individual patients identified
by the testing, namely in tumors driven by rare muta-
tions [31]. Thus, routine use of modern approaches,
such as next-generation sequencing resulting in dramatic
reduction of testing costs, is eagerly awaited.
It should be noted that the data discussed here reflect
the status quo in 2014, and molecular testing is evolving
fast with changes in testing methods being implemented.
The growing use of IHC for ALK testing has already
been discussed. In addition, many laboratories in Europe
are now adopting next-generation sequencing that can
be applied to formalin-fixed paraffin-embedded tissue in
routine diagnostic practice. This allows for the detection
of many genetic alterations and oncogene targets in par-
allel, providing the opportunity for fast and deep
characterization of tumors as well as for the potential
for other targeted therapies [32].
Adherence to the best practices in molecular testing is
crucial to ensure accurate diagnoses and appropriate
clinical decisions [30, 33]. Quality control is essential to
ensure consistent and reliable molecular diagnostic re-
sults and to facilitate comparison of results from differ-
ent laboratories. External quality assessment (EQA)
programs have been established for both EGFR and ALK
testing [33, 34]. The vast majority of the laboratories
contributing to this study already participate in EQA
programs. Many laboratories in the region participate in
the European Society of Pathology Lung External Qual-
ity Assessment Scheme [19]. As the results of molecular
testing directly influence the management of individual
patients, EQA is essential to guarantee optimal quality
of testing. Therefore, each laboratory should prove suc-
cessful participation in the appropriate EQA program to
be included to the network of testing centers [35].
Multidisciplinary tumor boards play a key role in opti-
mizing the diagnosis and treatment of lung cancer [30].
With rapid progress in the molecular profiling of
NSCLC and its increasing complexity, it is essential that
the tumor boards include specially trained molecular pa-
thologists, as well as molecular biologists, among the
tumor board members when discussing the best possible
treatment for each individual patient with NSCLC. Al-
though it is positive that all countries studied have im-
plemented lung cancer tumor boards, these are more
likely to be operational only in specialized lung cancer
treatment centers.
Conclusions
Non-small cell lung cancer molecular testing is estab-
lished in all CEE countries participating in this study.
The responses show that all countries follow guidelines
regarding EGFR and ALK testing, with most countries
testing only advanced stages of adenocarcinomas,
NSCLC-NOS, and NSCLC when an adenocarcinoma
component cannot be excluded. Most countries are still
undertaking testing on request and not implementing
the preferred reflex policy.
Limited reimbursement is a significant barrier to mo-
lecular testing in the region and a disincentive to reflex
testing. The authors recommend that testing should be
independently funded.
The results show that ensuring adequate NSCLC
samples and enabling wide access of eligible patients
to molecular testing are key issues for the future. In-
creasing the number of patients reviewed by multidis-
ciplinary boards and the access of patients with
druggable molecular alterations to targeted drugs are
other major challenges.
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